Business Description
Novacyt SA
ISIN : FR0010397232
Total Employee Number:
216Compare
Compare
Traded in other countries / regions
ALNOV.FranceNCYT.UKNYZ.GermanyNVYTF.USA IPO Date
2017-11-13Description
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, Yourgene Health and Corporate. Majority of the revenue is generated from Yourgene Health segment. Geographically, the company operates in United Kingdom, France, Europe, America, Asia-Pacific, Middle East and Africa generating majority from Asia- pacific region.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.83 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | -1.26 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.96 | |||||
Beneish M-Score | -3.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.9 | |||||
3-Year EBITDA Growth Rate | 11.4 | |||||
3-Year EPS without NRI Growth Rate | -3.8 | |||||
3-Year FCF Growth Rate | 11.4 | |||||
3-Year Book Growth Rate | -41.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.48 | |||||
9-Day RSI | 43.89 | |||||
14-Day RSI | 43.93 | |||||
3-1 Month Momentum % | 22.96 | |||||
6-1 Month Momentum % | 10.91 | |||||
12-1 Month Momentum % | -5.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.75 | |||||
Quick Ratio | 4.32 | |||||
Cash Ratio | 3.28 | |||||
Days Inventory | 129.53 | |||||
Days Sales Outstanding | 68.27 | |||||
Days Payable | 55.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 8.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.03 | |||||
Operating Margin % | -61.84 | |||||
Net Margin % | -113.56 | |||||
EBITDA Margin % | -40.95 | |||||
FCF Margin % | -49.53 | |||||
OCF Margin % | -45.12 | |||||
ROE % | -59.68 | |||||
ROA % | -38.52 | |||||
ROIC % | -32.36 | |||||
3-Year ROIIC % | -15.07 | |||||
ROC (Joel Greenblatt) % | -193.2 | |||||
ROCE % | -50.4 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.2 | |||||
PB Ratio | 1.04 | |||||
Price-to-Tangible-Book | 1.24 | |||||
EV-to-EBIT | -0.61 | |||||
EV-to-EBITDA | -2 | |||||
EV-to-Revenue | 0.81 | |||||
EV-to-FCF | -1.7 | |||||
Price-to-GF-Value | 0.58 | |||||
Price-to-Projected-FCF | 0.28 | |||||
Price-to-Median-PS-Value | 1.04 | |||||
| Price-to-Net-Current-Asset-Value | 2.34 | |||||
| Price-to-Net-Cash | 9.93 | |||||
Earnings Yield (Greenblatt) % | -163.28 | |||||
FCF Yield % | -39.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novacyt SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 23.222 | ||
| EPS (TTM) (€) | -0.369 | ||
| Beta | 3.6567 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 1.02 | ||
| Volatility % | 96.32 | ||
| 14-Day RSI | 43.93 | ||
| 14-Day ATR (€) | 0.03384 | ||
| 20-Day SMA (€) | 0.3998 | ||
| 12-1 Month Momentum % | -5.14 | ||
| 52-Week Range (€) | 0.2835 - 0.973 | ||
| Shares Outstanding (Mil) | 72.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novacyt SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novacyt SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-30 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-09-30 | In 84 days | ||
| General meeting for 2026 | 2026-06-30 11:00 | 0.38 (-2.54%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-30 10:00 | 0.37 (+3.55%) | ||
| Annual report for 2025 | 2026-04-30 | 0.37 (+3.55%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-30 | 0.37 (+3.55%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-30 | 0.44 (-2.11%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 0.44 (-2.11%) | ||
| General meeting for 2025 | 2025-06-19 12:00 | 0.46 (-7.68%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-04-30 11:00 | 0.42 (-7.35%) |
Show
Entries
Novacyt SA Frequently Asked Questions
What is Novacyt SA(STU:NYZ)'s stock price today?
The current price of STU:NYZ is €0.40. The 52 week high of STU:NYZ is €0.97 and 52 week low is €0.28.
When is next earnings date of Novacyt SA(STU:NYZ)?
The next earnings date of Novacyt SA(STU:NYZ) is 2026-09-30 Est..
Does Novacyt SA(STU:NYZ) pay dividends? If so, how much?
Novacyt SA(STU:NYZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Novacyt SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers